Severe Acute Respiratory Syndrome
Conditions
Interventions
A multicenter, observational, prospective cohort study will be carried out, with a comparison group and convenience sampling, to monitor adult patients with DRIM who have or are showing symptoms sugge
(2) prospective follow-up of the evolution of DRIM for six months after viral infection.
Other
E01.370.225.998.110
Sponsors
Socidade Brasileira de Reumatologia
Departamento de Ciência e Tecnologia - Decit
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age greater than or equal to 18 years; Diagnosis of DRIM defined according to the American College of Rheumatology (ACR) or European League against Rheumatism (EULAR), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), systemic sclerosis (ES), inflammatory myopathies , mixed connective tissue disease (DMTC), overlap syndrome, vasculitis, spondyloarthritis (AS), systemic sclerosis (ES); Current or past suspicion of COVID-19 infection; Understanding and signing the consent form of the patient or his legal representative. Inclusion criteria for the unexposed comparison group, age greater than or equal to 18 years; Diagnosis of DRIM defined according to the American College of Rheumatology (ACR) or European League against Rheumatism (EULAR), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), systemic sclerosis (ES), inflammatory myopathies , mixed connective tissue disease (DMTC), overlap syndrome, vasculitis, spondyloarthritis (AS), systemic sclerosis (ES); There were no symptoms suggestive of COVID-19 during the study collection period; Understanding and signing the consent form of the patient or his legal representative.
Exclusion criteria
Exclusion criteria: Immunosuppressed by other causes, such as people living with HIV, CD4 + <200 cells / mm3, organ transplantation, primary immunodeficiency, neoplasia, past history of diseases of the thymus myasthenia gravis, thymoma, cases of absence of thymus or removal surgical.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome: modification of disease activity status Disease activity will be assessed using specific instruments and validated for each DRIM. In order to determine the disease activity before the infection by COVID-19, a retrospective evaluation will be carried out through medical record review considering the medical visit made up to three months before the infection. Disease activity will also be assessed on inclusion and on all visits scheduled by the study. | — |
Secondary
| Measure | Time frame |
|---|---|
| Evolution for ARDS: yes or no o Outcome after ARDS: complete improvement, sequelae with pulmonary fibrosis, death Laboratory changes: leukopenia, lymphocytopenia, elevated CRP, elevated DHL (yes or no) o Change in dose of medication used: yes or noo Need to discontinue medication: yes or no Change in therapeutic regimen: yes or no; type of change | — |
Countries
Brazil
Contacts
Public Contactcláudia marques
Universidade Federal de Pernambuco
Outcome results
None listed